ESG Impact Zone

Illumina and Allegheny Health Network to Assess In-House Comprehensive Cancer Genomic Profiling to Enhance Patient Care

3BL Media

MAY 19, 2022

SOURCE: Illumina. DESCRIPTION: SAN DIEGO, May 18, 2022 /3BL Media/ -- Illumina, Inc. If so, less-invasive CGP testing of blood samples could potentially complement tissue sampling, substantially increasing the number of patients who are able to have their tumors profiled and be part of clinical trials for cancer therapy selection. "We

RNA Sequencing Critical to Identifying Key Fusions for Oncology Patients

3BL Media

NOVEMBER 8, 2022

At AMP 2022, Illumina in collaboration with Labcorp presents key abstracts demonstrating efficacy of CGP testing. SOURCE: Illumina. More than 100 abstracts accepted by AMP this year cite Illumina technology, with dozens using the Illumina TruSight Oncology 500 Research Assay (TSO 500) specifically. References.

Development

Illumina and Pillar Biosciences Partner To Improve Access to Personalized Cancer Treatment Options

3BL Media

JULY 31, 2023

SAN DIEGO, July 31, 2023 /3BL/ -- Illumina Inc. the pioneers of Decision Medicine™, announced a strategic partnership to make Pillar's suite of oncology assays commercially available globally as part of the Illumina portfolio of oncology products. "We Pillar's suite of oncology assays can be used on any of Illumina's sequencers.

Development

Development Manufacturing

Webinars

Manufacturing Sustainability Surge: Your Guide to Data-Driven Energy Optimization & Decarbonization

MORE WEBINARS

“All Patients Should Have Their Tumor Sequenced At Least Once”

3BL Media

JUNE 13, 2022

At ASCO 2022, an oncology panel discusses the benefits and practices of comprehensive genomic profiling. SOURCE: Illumina. A key topic was the implementation of comprehensive genomic profiling (CGP) in the clinic as a powerful approach to maximize cancer treatment options following diagnosis.

Academics

Illumina's Technology Supports Biodiversity and Conservation Initiatives

3BL Media

MARCH 4, 2022

Illumina Celebrates World Wildlife Day. SOURCE: Illumina. DESCRIPTION: Illumina’s innovations transcend beyond improving the health of humans to improving the health of all living things. Profiling endangered plant species to promote conservation . KEYWORDS: illumina, NASDAQ: ILMN, World Wildlife Day, biodiversity.

Development

Australia's PrOSPeCT Project Is Sequencing Thousands of Cancer Patients

3BL Media

JUNE 24, 2022

Public/private partnership expands access to comprehensive genomic profiling to improve patient care and advance drug discovery. SOURCE: Illumina. We picked up many patients who had nowhere else to go for genomic profiling or clinical trials.”. The Illumina Genomics Summit. Uniting Australia. INNOVATIVE TECHNOLOGIES.

Analytics

Analytics Development

Patient Success Story: Beating Stage IV Lung Cancer

3BL Media

FEBRUARY 11, 2022

SOURCE: Illumina. At Illumina, we are committed to leveraging the power of genomics to drive personalized medicine and positively impact human health. Illumina invests deeply in research and is developing in vitro diagnostic (IVD) tests that have the potential to improve the patient’s therapy journey and outcomes.

Development

Illumina Collaborates With National Cancer Center Japan to Address a Leading Cause of Death in Asia

3BL Media

FEBRUARY 4, 2022

SOURCE: Illumina. DESCRIPTION: SAN DIEGO, February 4, 2022 /3BL Media/ -- Illumina, Inc. We are immensely proud to contribute to this international collaboration and prospective study," said Gretchen Weightman, Head of Global Commercial Strategy and General Manager of Asia Pacific and Japan at Illumina. About Illumina.

Development

Development Analytics

Illumina and GenoScreen Partner To Expand Access to Genomic Testing for Multidrug-Resistant Tuberculosis

3BL Media

OCTOBER 19, 2022

SOURCE: Illumina. DESCRIPTION: SAN DIEGO, October 19, 2022 /3BL Media/ -- Illumina Inc. Through our partnership, we will enable lower-income countries to confront the pervasive threat of TB and work toward eliminating it," said Phil Febbo, chief medical officer of Illumina.

Development

Development Manufacturing

Illumina Introduces New Research Test to Address One of the Most Common Infections in the United States

3BL Media

NOVEMBER 3, 2022

SOURCE: Illumina. DESCRIPTION: SAN DIEGO, November 3, 2022 /3BL Media/ -- Illumina, Inc. This announcement comes after the October launch of two research tests enabling high-risk virus surveillance, as part of Illumina's steadfast commitment to supporting global preparedness for epidemic and pandemic outbreaks.

Illumina Unveils Groundbreaking Comprehensive Genomic Profiling Test for Cancer in Europe

3BL Media

MARCH 16, 2022

SOURCE: Illumina. DESCRIPTION: SAN DIEGO, March 16, 2022 /3BL Media/ -- Illumina, Inc. NASDAQ:ILMN) announced the launch of TruSight™ Oncology (TSO) Comprehensive (EU), a single test that assesses multiple tumor genes and biomarkers to reveal the specific molecular profile of a patient's cancer.

Manufacturing

Manufacturing Development

Illumina Announces Long-Term Strategic Partnership with Janssen

3BL Media

MAY 2, 2022

SOURCE: Illumina. Illumina data analytics platforms and collaborative lab services will enable more effective and efficient drug discovery by harnessing the power of genomics. DESCRIPTION: By Joydeep Goswami Chief Strategy and Corporate Development Officer at Illumina. Illumina can help deliver precision medicine at scale.

Data Analytics

Data Analytics Development Analytics Manufacturing

Latest Research at ESMO Congress 2022 Showcases the Impact of Comprehensive Genomic Profiling for Cancer Patients

3BL Media

SEPTEMBER 7, 2022

SOURCE: Illumina. DESCRIPTION: SAN DIEGO, September 7, 2022 / 3BL Media / — Illumina, Inc. For oncologists, the priority for each patient is to provide the best course of therapy as early as possible,” said Dr. Phil Febbo, chief medical officer of Illumina.

Analytics

Analytics Academics

How Comprehensive Genomic Profiling Is Helping Cancer Patients Today

3BL Media

SEPTEMBER 23, 2022

SOURCE: Illumina. DESCRIPTION: The European Society of Medical Oncology (ESMO) annual congress convened earlier this month in Paris, where, Illumina presented key abstracts demonstrating the clinical utility of comprehensive genomic profiling (CGP). Learn more about Illumina here.

Development

Video: Merging Discovery With Clinical Care at Ontario Institute for Cancer Research

3BL Media

NOVEMBER 30, 2023

Originally published on Illumina News Center In the middle of downtown Toronto, surrounded by major universities and hospitals, the Ontario Institute for Cancer Research (OICR) is working to better understand tumor biology and improve cancer care. Fortunately, current Illumina sequencers are fast. Cancer does not wait.

Development

Illumina Partners With Centers Across France to Advance a Precision Medicine Approach for Patients With Late-Stage Cancer

3BL Media

FEBRUARY 7, 2022

Joint study will assess clinical value of comprehensive genomic profiling (CGP) on cancer therapy options in patients with advanced disease. SOURCE: Illumina. DESCRIPTION: SAN DIEGO, February 7, 2022 /3BL Media/ -- Illumina, Inc. We are grateful for Illumina's contribution to this project.".

Analytics

Analytics Development

Delivering the Future of Diagnostics and Precision Oncology

3BL Media

SEPTEMBER 9, 2022

At ECP 2022, Illumina presents new validation for TSO Comprehensive. SOURCE: Illumina. Illumina Director of Product Development Victor Sementchenko will deliver a presentation during the session, Molecular Pathology Diagnostics and Translational Research Symposium. Sementchenko’s project involved dozens of studies.

Analytics

Analytics Development

Why More Clinical Labs Are Turning to Whole-Genome Sequencing for Cancer

3BL Media

APRIL 5, 2024

Originally published on Illumina News Center Whole-genome sequencing (WGS) use is more established for rare and pediatric disease, but next-generation sequencing in clinical use for cancer consists of various approaches. That same year, Medicare Administrative Contractor MolDX approved reimbursement of WGS for AML.

Academics

Academics Logistics Development

Illumina Introduces New Pan-Cancer Companion Diagnostic to Match Patients With Rare Genetic Mutations to Targeted Therapy

3BL Media

MAY 24, 2022

First companion diagnostic claim for Illumina's TruSight™ Oncology Comprehensive (EU) test enables targeted therapy with Bayer's VITRAKVI® (larotrectinib) for patients with NTRK fusion cancer. SOURCE: Illumina. DESCRIPTION: SAN DIEGO, May 24, 2022 /3BL Media/ -- Illumina, Inc.

Development

Development Manufacturing Analytics

Illumina Launches Research Test Codeveloped With Merck To Unlock Deeper Insights Into the Tumor Genome

3BL Media

JUNE 22, 2022

New assay brings validated HRD technology from Myriad Genetics to the Illumina TruSight™ Oncology 500, a single, comprehensive pan-cancer test to identify key variants critical for cancer development and progression. SOURCE: Illumina. DESCRIPTION: SAN DIEGO, June 22, 2022 /3BL Media/ -- Illumina, Inc.

Development

Development Shipping

Illumina Unveils Its Most Accurate and Comprehensive Secondary Analysis Platform, Boosting Lab Capabilities

3BL Media

JULY 27, 2022

SOURCE: Illumina. DESCRIPTION: SAN DIEGO, July 27, 2022 /3BL Media/ -- Illumina, Inc. NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the release of Illumina DRAGEN™ v4.0, Innovation is at the core of what we do at Illumina and we've made DRAGEN v4.0 About Illumina?.

Development

Development Manufacturing

A Liquid Biopsy Study Offers New Hope for Lung Cancer Patients

3BL Media

JULY 11, 2023

Originally published on Illumina News Center Lung cancer patients in Wales are about to get answers faster—and potentially find out if they’re a match for targeted therapies. The approach is known as comprehensive genomic profiling (CGP) and it can assess multiple biomarkers in numerous tumor types in a single NGS assay.

Analytics

New Research Shows CGP Is Most Effective as a Standalone Test

3BL Media

JULY 26, 2023

Originally published on Illumina News Center Comprehensive genomic profiling (CGP) assesses hundreds of tumor genes to find actionable mutations and is becoming the standard of care for many cancers. However, oncologists often opt for single-gene tests (SGT) before pursuing CGP.

Development

ESG Impact Zone

Illumina and Allegheny Health Network to Assess In-House Comprehensive Cancer Genomic Profiling to Enhance Patient Care

RNA Sequencing Critical to Identifying Key Fusions for Oncology Patients

Webinars

Trending Sources

Illumina and Pillar Biosciences Partner To Improve Access to Personalized Cancer Treatment Options

Webinars

“All Patients Should Have Their Tumor Sequenced At Least Once”

Illumina's Technology Supports Biodiversity and Conservation Initiatives

Australia's PrOSPeCT Project Is Sequencing Thousands of Cancer Patients

Patient Success Story: Beating Stage IV Lung Cancer

Illumina Collaborates With National Cancer Center Japan to Address a Leading Cause of Death in Asia

Illumina and GenoScreen Partner To Expand Access to Genomic Testing for Multidrug-Resistant Tuberculosis

Illumina Introduces New Research Test to Address One of the Most Common Infections in the United States

Illumina Unveils Groundbreaking Comprehensive Genomic Profiling Test for Cancer in Europe

Illumina Announces Long-Term Strategic Partnership with Janssen

Latest Research at ESMO Congress 2022 Showcases the Impact of Comprehensive Genomic Profiling for Cancer Patients

How Comprehensive Genomic Profiling Is Helping Cancer Patients Today

Video: Merging Discovery With Clinical Care at Ontario Institute for Cancer Research

Illumina Partners With Centers Across France to Advance a Precision Medicine Approach for Patients With Late-Stage Cancer

Delivering the Future of Diagnostics and Precision Oncology

Why More Clinical Labs Are Turning to Whole-Genome Sequencing for Cancer

Illumina Introduces New Pan-Cancer Companion Diagnostic to Match Patients With Rare Genetic Mutations to Targeted Therapy

Illumina Launches Research Test Codeveloped With Merck To Unlock Deeper Insights Into the Tumor Genome

Illumina Unveils Its Most Accurate and Comprehensive Secondary Analysis Platform, Boosting Lab Capabilities

A Liquid Biopsy Study Offers New Hope for Lung Cancer Patients

New Research Shows CGP Is Most Effective as a Standalone Test

Stay Connected